Updates in Therapies of Relapse/Refractory Follicular Lymphoma

Connie Batlevi, MD, PhD, discusses the rate of patient relapse and current treatment options and considerations for relapsed/refractory follicular lymphoma.

An expert in follicular lymphoma highlights the therapies available for third-line relapsed/refractory treatment options.

Connie Batlevi, MD, PhD, explains the recent approval of tazemetostat, as well as the use of molecular testing in follicular lymphoma.

Connie Batlevi, MD, PhD, discusses how the sequencing of follicular lymphoma therapies has changed in the past year and looks to the future with the upcoming American Society of Hematology (ASH) annual meeting.

Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast.

In this CancerNetwork® OncView™ program, faculty panelist Connie Batlevi, MD, PhD, explains the treatment options in this disease space and discusses a recent drug approval.